This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $188,024 to the University of Washington to investigate local and systemic immune responses during syphilis infection. The key objectives are to identify dominant and prevalent Treponema pallidum (TP) CD4 T cell antigens, examine whether lesion plasma cells secrete TP-specific IgG, and characterize the innate immune response in active and healed syphilis lesions. The research aims to improve the ability to design next-generation syphilis vaccine candidates by advancing the understanding of acquired and innate immunity against TP. The grant period is from June 1, 2024 to May 31, 2029.
Generated 2/25/25, 4:19 AM